A federal advisory panel has narrowly voted to recommend easing FDA restrictions on the compounding of specific peptides, including BPC-157 and TB-500. This advice, which is not binding, contradicts FDA scientists who warn of insufficient safety and efficacy data. The decision aligns with the views of Health Secretary Robert F. Kennedy Jr. and could lead to increased availability of these substances through telehealth and compounding pharmacies.
The most-used peptide combinations, what the research actually says, and where to buy — one page, one email.
No spam. Unsubscribe anytime.